Monte Rosa Therapeutics Commences Offering Of $200M Common Stock, Pre-Funded Warrants

Monte Rosa Therapeutics, Inc. ("Monte Rosa") (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has commenced an underwritten public offering of $200.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. All of the shares of common stock and pre-funded warrants to purchase shares of common stock in the proposed offering are to be sold by Monte Rosa. Monte Rosa also intends to grant the underwriters a 30-day option to purchase up to an additional $30.0 million of shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.